Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Taking The Temperature Of Accelerated Approval: An Interview With Ariad's President Of R&D Tim Clackson: (Part 2 Of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

R&D head reflects on the accelerated approval program in the wake of FDA's February meeting with ODAC.
Advertisement

Related Content

Pfizer's Crizotinib Eases Past FDA With Targeted Population
Zelboraf Approval Hastened By FDA Officials Impressed With Early Efficacy
Adcetris Review Adds Some Clarity To Principles For Accelerated Approval
Adcetris Review Adds Some Clarity To Principles For Accelerated Approval
Survival Data For Pfizer's Crizotinib Appears Promising, Positioning It For Accelerated Approval

Topics

Advertisement
UsernamePublicRestriction

Register

PS072714

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel